STOCK TITAN
  1. Home
  2. News
  3. RNAZ

TransCode Therapeutics, Inc. - RNAZ STOCK NEWS

Welcome to our dedicated page for TransCode Therapeutics news (Ticker: RNAZ), a resource for investors and traders seeking the latest updates and insights on TransCode Therapeutics stock.

TransCode Therapeutics, Inc. (NASDAQ: RNAZ) is a Boston-based clinical-stage biopharmaceutical company dedicated to combating metastatic disease through the discovery, development, and commercialization of novel microRNA (miRNA) therapeutics. The company's pioneering work centers around its proprietary TTX nanoparticle platform, designed to effectively deliver RNA-based therapies to target and treat various cancers.

The lead therapeutic candidate of TransCode Therapeutics, TTX-MC138, focuses on metastatic tumors that overexpress microRNA-10b, a well-known biomarker associated with metastasis. This candidate is currently undergoing rigorous clinical trials, with initial results indicating promising accumulation of the therapy in metastatic lesions.

The company also boasts a diverse pipeline of RNA therapeutic candidates, including TTX-siPDL1 and TTX-RIGA, aimed at overcoming the delivery challenges of RNA therapies and addressing novel genetic targets relevant to different cancer types. TransCode is actively engaged in expanding its research collaborations, as highlighted by its project combining the TTX platform with Debiopharm’s drug delivery technologies.

However, TransCode faces noteworthy financial and regulatory challenges. Recent communications reveal that the company is addressing compliance issues with Nasdaq listing requirements and the potential need for a reverse stock split to maintain its listing status. Despite these hurdles, TransCode remains committed to advancing its research and development efforts, securing strategic partnerships, and raising sufficient capital to drive its innovative pipeline forward.

TransCode’s vision extends beyond treating metastatic cancer; they aim to revolutionize cancer therapy by creating highly selective treatments that trigger the immune response against tumors while sparing healthy tissues. This approach is exemplified by their tumor-selective RIG-I agonists currently in development.

News

Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock Market

Rhea-AI Summary
TransCode Therapeutics, Inc. (Nasdaq: RNAZ) has received notice from the Nasdaq Stock Market LLC that it has regained compliance with the minimum stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1) for continued listing. The company will be subject to a mandatory panel monitor through January 26, 2025. Additionally, the company was notified that it was not in compliance with the minimum bid price rule, and it must regain compliance by May 6, 2024, or be eligible for an additional 180 calendar day compliance period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.3%
Tags
none
-
News

TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer

Rhea-AI Summary
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) announces a co-research agreement with Debiopharm to explore combining TransCode’s proprietary TTX delivery platform with Debiopharm’s expertise in targeted drug delivery to co-develop targeted nucleic acid therapeutics for cancer. The collaboration aims to test the development of new targeted nucleic acid delivery modalities, with the potential to revolutionize cancer research and treatment. TransCode's lead therapeutic candidate, TTX-MC138, designed to use antisense technology to treat metastatic cancer, is being evaluated in an early-stage clinical trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.63%
Tags
none
-
News

TransCode Therapeutics Announces Closing of $7.25 Million Public Offering

Rhea-AI Summary
TransCode Therapeutics, Inc. (RNAZ) has closed a public offering, raising $7.25 million in gross proceeds. The offering included 5,942,623 shares of common stock and warrants to purchase up to 11,885,246 shares at a price of $1.22 per share. The company plans to use the net proceeds for product development activities, including clinical trials with its lead therapeutic candidate, TTX-MC138, and for general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.43%
Tags
offering
News

TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering

Rhea-AI Summary
TransCode Therapeutics, Inc. (RNAZ) announces the pricing of a public offering of 5,942,623 shares of common stock and warrants to purchase up to 11,885,246 shares at a combined public offering price of $1.22 per share. The warrants will have an exercise price of $1.22 per share and will expire three and one-half years from the date of issuance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-49.54%
Tags
offering
-
News

TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO

Rhea-AI Summary
TransCode Therapeutics, Inc. (RNAZ) reported further steps in its restructuring to reduce expenditures and focus on its lead therapeutic candidate. The CEO announced his retirement, and the CFO will become interim CEO. The Chief Technology Officer has been promoted to Chief Scientific Officer, and the Chairman of the Board of Directors will assume the position of Executive Chairman.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.8%
Tags
clinical trial
-
News

TransCode Therapeutics Announces 1-for-40 Reverse Stock Split

Rhea-AI Summary
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) announced a 1-for-40 reverse stock split to increase the per share trading price and satisfy the minimum bid price requirement for continued listing on the Nasdaq Capital Market. The reverse split will reduce the number of shares of outstanding common stock from approximately 25,097,596 shares to approximately 627,448 shares.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.57%
Tags
stock split
News

TransCode Therapeutics Publishes Open Letter Outlining Company’s Progress and Objectives

Rhea-AI Summary
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) raised $18.5M in capital despite difficult financial markets and initiated its first clinical trial for its lead therapeutic candidate, TTX-MC138, designed to treat metastatic disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.18%
Tags
none
-
News

TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138

Rhea-AI Summary
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) successfully completed a preclinical study on its lead therapeutic candidate, TTX-MC138, in pancreatic adenocarcinoma, demonstrating its effectiveness against metastatic pancreatic cancer in animal models.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.57%
Tags
clinical trial
-
News

TransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium

Rhea-AI Summary
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) will present data from a Phase 0 clinical trial with its lead candidate, TTX-MC138, at the San Antonio Breast Cancer Symposium. The trial involves injection of a microdose of Cu64-labeled TTX-MC138 into stage IV breast cancer patients, followed by PET-MRI to determine the pharmacokinetics of TTX-MC138 and its uptake in metastatic lesions. The company believes that these data show the potential for TTX-MC138 to accumulate in human metastases, support further clinical development, and enable clinical development of a wide array of TTX-based therapeutic candidates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.95%
Tags
conferences
News

TransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules

Rhea-AI Summary
TransCode Therapeutics, Inc. (Nasdaq: RNAZ) has closed a registered direct offering, selling 5,000,000 shares of common stock at $0.242 per share, resulting in gross proceeds of $1.2 million. The company plans to use the net proceeds for clinical trials with its lead therapeutic candidate, TTX-MC138, and for general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.95%
Tags
offering

FAQ

What is the current stock price of TransCode Therapeutics (RNAZ)?

The current stock price of TransCode Therapeutics (RNAZ) is $0.3845 as of November 22, 2024.

What is the market cap of TransCode Therapeutics (RNAZ)?

The market cap of TransCode Therapeutics (RNAZ) is approximately 6.6M.

What does TransCode Therapeutics, Inc. specialize in?

TransCode Therapeutics specializes in developing RNA-based therapeutic candidates targeting metastatic diseases using its proprietary TTX nanoparticle platform.

What is TTX-MC138?

TTX-MC138 is TransCode's lead therapeutic candidate focused on treating metastatic tumors that overexpress microRNA-10b, a marker associated with metastasis.

What are the challenges TransCode Therapeutics is facing?

TransCode is facing challenges related to meeting Nasdaq listing requirements and may need to consider a reverse stock split to maintain its listing status.

What is the significance of the TTX nanoparticle platform?

The TTX nanoparticle platform enables the precise delivery of RNA therapeutics, overcoming delivery challenges and potentially unlocking treatments for various cancers.

What recent project involves TransCode’s TTX platform?

A recent project involves testing the combination of TransCode’s TTX delivery platform with Debiopharm’s drug delivery technologies.

What is the clinical status of TTX-MC138?

TTX-MC138 is currently in clinical trials, with initial data indicating effective accumulation in metastatic lesions.

How does TransCode aim to innovate cancer therapy?

TransCode aims to innovate cancer therapy by developing treatments that selectively trigger the immune system to attack tumors while sparing healthy tissues.

What are some other RNA therapeutic candidates in TransCode’s pipeline?

Other candidates include TTX-siPDL1 and TTX-RIGA, designed to address novel genetic targets relevant to various types of cancer.

Who can I contact for more information about TransCode Therapeutics?

For more information, you can contact Tania Montgomery-Hammon, VP of Business Development, at tania.montgomery@transcodetherapeutics.com.

What are TransCode’s goals for 2024?

TransCode aims to strengthen its organization, raise capital, expand strategic partnerships, and advance both its clinical and preclinical portfolios.

Stock RNAZ logo
TransCode Therapeutics, Inc.

Nasdaq:RNAZ

RNAZ Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

RNAZ Stock Data

6.64M
17.26M
0.01%
1.99%
4.31%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BOSTON